HGH FRAG 176-191 · 10 MG | Ataca la Grasa. Revela la Definición.

Key Benefits of HGH Frag 176-191 Lipolysis Stimulation for Selective Fat Loss HGH Frag 176-191 activates the breakdown of stored triglycerides in adipocytes through activation of hormone-sensitive lipase (HSL). This process releases free fatty acids and glycerol into the bloodstream, where they are transported to peripheral tissues to be oxidized as an energy source . Unlike other lipolytic agents that act systemically, HGH Frag 176-191 has a particular affinity for visceral and abdominal adipose tissue, the areas most resistant to fat loss through conventional diet and exercise. Lipogenesis Inhibition to Prevent Fat Accumulation In addition to stimulating fat breakdown, HGH Frag 176-191 inhibits the process of lipogenesis, the formation and storage of new fat deposits . This means that even under conditions of elevated caloric intake, the peptide helps prevent the accumulation of new adipose tissue. This dual effect —stimulating the burning of existing fat while blocking new fat formation— makes HGH Frag 176-191 an extremely effective agent for body recomposition. Preservation of Lean Muscle Mass During caloric deficit periods, the body tends to use both fat and muscle tissue as energy sources. HGH Frag 176-191 promotes fatty acid oxidation as a primary fuel source, thus preserving muscle glycogen and structural proteins . This allows athletes and bodybuilders to maintain their hard, dense muscle mass while reducing body fat percentage, achieving a drier, more defined, and vascular appearance without sacrificing hard-earned tissue. No IGF-1 Effects and Associated Risks One of the most significant advantages of HGH Frag 176-191 over full growth hormone is that it does not activate the growth hormone receptor (GHR), therefore it does not elevate insulin-like growth factor type 1 (IGF-1) levels . This eliminates the risks associated with full HGH, such as unwanted cell proliferation, insulin resistance, fluid retention, internal organ hypertrophy, and carpal tunnel syndrome development. The fragment acts specifically on adipose tissue without affecting systemic anabolic pathways. Improved Insulin Sensitivity and Metabolic Profile Reduction of visceral fat, especially deep abdominal fat, is closely associated with better insulin sensitivity and a healthier metabolic profile . By reducing adipose tissue, HGH Frag 176-191 contributes to decreased systemic inflammation and improved glucose regulation, which has positive implications for overall metabolic health and athletic performance. Increased Fatty Acid Oxidation During Exercise HGH Frag 176-191 stimulates β-oxidation of fatty acids in mitochondria, increasing the efficiency with which the body burns fat as fuel during exercise . This is especially beneficial during low and moderate intensity training, where fat oxidation is the primary energy system. By increasing the body&amp;#039;s capacity to utilize fat as an energy source, HGH Frag 176-191 improves endurance and work capacity during prolonged training sessions. Support for Muscle Definition and Overall Aesthetics In addition to fat loss, HGH Frag 176-191 contributes to an overall improved aesthetic through several mechanisms: Greater muscle definition: Reduction of the subcutaneous fat layer reveals underlying musculature, improving definition and vein appearance (vascularity). Firmer skin: Subcutaneous fat reduction results in firmer, muscle-adherent skin. Improved body composition: The combination of fat loss and muscle preservation results in a more athletic and aesthetic body composition.

Function and Mechanism of Action of HGH Frag 176-191 HGH Frag 176-191 is a synthetic peptide fragment corresponding to amino acids 176-191 of the C-terminal end of human growth hormone (GH). This fragment was identified as the region of the GH molecule responsible for its lipolytic properties, that is, fat mobilization and burning . Unlike full GH, HGH Frag 176-191 does not bind to the growth hormone receptor (GHR) and therefore does not activate signaling pathways associated with IGF-1 production. Detailed Mechanism of Action: Lipolysis Activation: HGH Frag 176-191 stimulates the activity of hormone-sensitive lipase (HSL) in adipocytes, the enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol . This activation occurs through receptor-mediated signaling on the adipocyte membrane, which triggers an intracellular signaling cascade resulting in HSL phosphorylation and activation. The net result is the release of free fatty acids into the bloodstream, where they can be transported to peripheral tissues for oxidation as an energy source. Lipogenesis Inhibition: In addition to stimulating fat breakdown, HGH Frag 176-191 inhibits the process of lipogenesis, the formation and storage of new fat deposits . This is achieved through inhibition of key enzymes involved in fatty acid synthesis, such as fatty acid synthase (FAS) and acetyl-CoA carboxylase. This dual effect —stimulating the burning of existing fat while blocking new fat formation— makes HGH Frag 176-191 an extremely effective agent for body recomposition. No IGF-1 Effects: One of the distinctive features of HGH Frag 176-191 is that it does not activate the growth hormone receptor (GHR), therefore it does not elevate insulin-like growth factor type 1 (IGF-1) levels . This eliminates the risks associated with full HGH, such as unwanted cell proliferation, insulin resistance, fluid retention, and internal organ hypertrophy. The fragment acts specifically on adipose tissue without affecting systemic anabolic pathways. Stimulation of β-Oxidation of Fatty Acids: HGH Frag 176-191 stimulates β-oxidation of fatty acids in the mitochondria of peripheral tissues, increasing the efficiency with which the body burns fat as fuel . This process involves the sequential breakdown of fatty acids into acetyl-CoA units, which then enter the Krebs cycle to generate ATP, the primary cellular energy source. Differentiation from AOD9604: HGH Frag 176-191 differs from other HGH fragments such as AOD9604 in several key aspects. While AOD9604 has been associated with stimulation of thyroid hormone release and effects on carbohydrate metabolism, HGH Frag 176-191 acts more specifically on adipose tissue, with a cleaner action profile and no effects on thyroid function .

How to Use HGH Frag 176-191 Route of Administration: Injectable via subcutaneous (SC). Subcutaneous administration is the standard method for HGH Frag 176-191, allowing gradual and constant absorption. Injection sites should be rotated (abdomen, thigh, gluteal region) to avoid local irritation and ensure uniform absorption. Reconstitution: The product is presented as a lyophilized powder in a sterile vial. It must be reconstituted with bacteriostatic water for injection (or sterile water for injection) before use. Add the diluent slowly, gently swirling the vial to dissolve the powder. Do not shake vigorously to avoid peptide degradation. Research Protocol: Dosage and frequency must be determined by the researcher according to protocol goals. Common research protocols for HGH Frag 176-191 use: Dose: 200-500 mcg per administration, 1-2 times daily . Frequency: Daily or every other day administration for 4-12 weeks to achieve desired results . Timing of Administration: Ideally administered on an empty stomach, in the morning upon waking or before fasted exercise, to maximize fat oxidation as an energy source. Storage: The lyophilized powder should be stored in a cool, dry place, protected from light and at controlled temperature (2-8°C). Once reconstituted, it must be refrigerated (2-8°C) and used within 30 days. Important Notice: Product intended EXCLUSIVELY FOR SCIENTIFIC RESEARCH in vitro and in animal models. HGH Frag 176-191 is not FDA-approved for any human use. Reported side effects are generally mild and may include redness at the injection site, mild nausea, and in rare cases, headache or dizziness. Its use carries risks and the researcher is solely responsible for safety and compliance with applicable regulations during protocol development.

Ingredients of HGH Frag 176-191 Active Ingredient: HGH Frag 176-191 (Human Growth Hormone Fragment 176-191): A synthetic peptide fragment corresponding to amino acids 176-191 of the C-terminal end of human growth hormone. Sequence: H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-NH₂. Acts specifically on adipose tissue stimulating lipolysis and inhibiting lipogenesis, without affecting IGF-1 levels. The active ingredient purity is ≥99% by HPLC-MS. Excipients: Mannitol: A sugar alcohol that acts as a cryoprotectant and bulking agent, used to stabilize the peptide structure during the lyophilization process. Water for Injection (WfI): High-purity water (USP/EP grade) used as a vehicle in the lyophilization process. Note for Researchers: This product is a high-purity synthetic peptide (&amp;gt;99% by HPLC-MS), manufactured without unnecessary additives, preservatives, or fillers. Its production is carried out under strict quality control standards (GMP). HGH Frag 176-191 is not FDA-approved for human use and is intended exclusively for in vitro and animal model scientific research.

Onset Time &amp;amp; Expected Results of HGH Frag 176-191 Onset of Action (Days to Weeks): HGH Frag 176-191 begins acting within the first hours after administration, with fat metabolism effects observed within the first days. Lipolysis activation and free fatty acid release occur shortly after administration, although visible changes in body composition require consistent use. Measurable Benefits (4-6 Weeks): The first measurable changes in body composition, including reduction in body fat percentage and improvement in muscle definition, begin to be visible within the first 4-6 weeks of consistent use according to the research protocol. Users report a noticeable decrease in abdominal fat and a drier, more defined appearance. Full Effect (8-12 Weeks): For maximum fat loss and complete muscle definition, the full effect often requires 8-12 weeks of consistent use according to the research protocol. Cumulative results include significant reduction in body fat percentage, greater muscle definition, and a more athletic and aesthetic body composition. Factors Influencing Results: The speed and magnitude of results depend on dose administered, administration frequency, adherence to the research protocol, nutrition quality, caloric deficit, training type, and individual metabolism.

Clinical Research &amp;amp; 3rd Party Test Results of HGH Frag 176-191 Scientific evidence on HGH Frag 176-191 comes primarily from preclinical studies in animal models and in vitro studies, as the compound is intended exclusively for research. Research has demonstrated its effects on lipolysis, lipogenesis inhibition, and muscle mass preservation. Preclinical and Laboratory Evidence: Lipolysis Studies: Research has demonstrated that HGH Frag 176-191 stimulates free fatty acid release from adipocytes through activation of hormone-sensitive lipase (HSL) . This effect is specific to adipose tissue and does not affect other tissues or organs. Lipogenesis Studies: HGH Frag 176-191 has been shown to inhibit new fat deposit formation through inhibition of key enzymes in fatty acid synthesis, such as fatty acid synthase (FAS) and acetyl-CoA carboxylase . Muscle Preservation Studies: In animal models, HGH Frag 176-191 has been shown to preserve lean muscle mass during caloric deficit periods, promoting fatty acid oxidation as an energy source . No IGF-1 Effects: Studies have confirmed that HGH Frag 176-191 does not activate the growth hormone receptor (GHR) and therefore does not elevate IGF-1 levels, avoiding side effects associated with full HGH . Comparison with AOD9604: HGH Frag 176-191 differs from other HGH fragments such as AOD9604 in several key aspects: Specificity: HGH Frag 176-191 acts more specifically on adipose tissue, with a cleaner action profile. No Thyroid Effects: Unlike AOD9604, which has been associated with stimulation of thyroid hormone release, HGH Frag 176-191 does not affect thyroid function . Mechanism of Action: Both fragments act through different mechanisms, with HGH Frag 176-191 being more selective for direct lipolysis. Regulatory Status: FDA Classification: HGH Frag 176-191 is not classified or approved by FDA for any use in the United States. Research Use: HGH Frag 176-191 is available for in vitro and animal model scientific research. Safety Considerations: Reported side effects are generally mild and include redness at the injection site, mild nausea, and in rare cases, headache or dizziness. Its use carries risks and is not recommended without medical supervision. Syntex Labs Quality Standards: Lab Grade: Purity ≥99% by HPLC-MS. QR Tracking: Complete batch traceability. Secure Batch Label: &amp;quot;Scratch to See&amp;quot; security system. 3rd Party Results: Access to Certificates of Analysis (COA) from accredited external laboratories.

Product Details

HGH FRAG 176-191 · 10 MG | Ataca la Grasa. Revela la Definición.

HGH FRAG 176-191 · 10 MG | Ataca la Grasa. Revela la Definición.

Build Your Stack

Frequently Asked Questions